{"entity":{"id":"nct07299825","kind":"trial","name":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","aka":[],"tldr":"A phase 2 trial of A166 in HER2-positive breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","summary":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07299825 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 40 participants planned, started 2024-09-20 and due to reach its primary completion in 2027-09-20. Interventions recorded: A166.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07299825","url":"https://clinicaltrials.gov/study/NCT07299825"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["a166"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07299825","phase":"2","setting":"Phase 2 Study of A166 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With TOP1-ADCs","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":40,"outcomes":[]},"route":"/trials/nct07299825/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"a166","kind":"drug","name":"A166","route":"/drugs/a166/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}